Source: ERJ Open Res, 6 (4) 00457-2020; 10.1183/23120541.00457-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Andreas Renner, Katharina Marth, Karin Patocka, Marco Idzko, Wolfgang Pohl. COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth. ERJ Open Res, 6 (4) 00457-2020; 10.1183/23120541.00457-2020

Member's Comments

No comment yet.

Related content which might interest you: Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab Source: ERJ Open Res, 6 (4) 00339-2020; 10.1183/23120541.00339-2020 Year: 2020 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study. Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 LATE-BREAKING ABSTRACT: Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma Source: Annual Congress 2012 - Late breaking results: Asthma from phenotyping to emerging new treatments Year: 2012 Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020